Caveolin-3 is a sensitive and specific marker for rhabdomyosarcoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 13, Issue 3, 2005, Pages 231-236

  Fine, Samson W ^a   Lisanti, Michael P ^a   Argani, Pedram ^b   Li, Maomi ^a,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Caveolin 3; myoD1; Myogenin; Rhabdomyosarcoma; Skeletal muscle

Indexed keywords

CAVEOLIN 3; MYOD1 PROTEIN; MYOGENIN; STRUCTURAL PROTEIN;

ANGIOSARCOMA; ARTICLE; CANCER DIAGNOSIS; CAV3 GENE; CELL DIFFERENTIATION; CELL TYPE; DIAGNOSTIC VALUE; EWING SARCOMA; GENE; HISTIOCYTOMA; HUMAN; HUMAN TISSUE; KNOCKOUT MOUSE; LEIOMYOSARCOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MELANOMA; MIXED MULLERIAN TUMOR; NEUROBLASTOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SENSITIVITY AND SPECIFICITY; SKELETAL MUSCLE; TRANSGENE;

CELL DIFFERENTIATION; HUMANS; MIXED TUMOR, MULLERIAN; MUSCLE CELLS; MUSCLE, SKELETAL; MYOD PROTEIN; MYOGENIN; RHABDOMYOSARCOMA; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

EID: 23944462875     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/00129039-200509000-00003     Document Type: Article

References (37)

1. Okamoto T, Schlegel A, Scherer PE, et al. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem. 1998;273:5419-5422.
2. Engelman JA, Zhang XL, Galbiati F, et al. Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1, -2, and -3). FEBS Lett. 1998;429:330-336.
3. Song KS, Scherer PE, Tang ZL, et al. Expression of caveolin-3 in skeletal, cardiac, and smooth muscle. J Biol Chem. 1996;271:15160-15165.
4. Scherer PE, Lewis RY, Volonte D, et al. Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo. J Biol Chem. 1997;272:29337-29346.
5. Bonilla E, Fishbeck K, Schotland D. Freeze-fracture studies of muscle caveolae in human muscular dystrophy. Am J Pathol. 1981;104:167-173.
6. Repetto S, Bado M, Broda P, et al. Increased number of caveolae and caveolin-3 overexpression in Duchenne muscular dystrophy. Biochem Biophys Res Commun. 1999;261:547-550.
7. Vaghy PL, Fang J, Wu W, et al. Increased caveolin-3 levels in mdx mouse muscles. FEBS Lett. 1998;431:125-127.
8. Galbiati F, Volonte D, Chu JB, et al. Transgenic overexpression of caveolin-3 in skeletal muscle fibers induces a Duchenne-like muscular dystrophy phenotype. Proc Natl Acad Sci USA. 2000;97:9689-9694.
9. Galbiati F, Razani B, Lisanti MR. Caveolae and caveolin-3 in muscular dystrophy. Trends Mol Med. 2001;7:435-441.
10. Galbiati F, Engelman JA, Volonte D, et al. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities. J Biol Chem. 2001;276:21425-21433.
11. Anderson RG. Plasmalemmal caveolae and GPI-anchored membrane proteins. Curr Opin Cell Biol. 1993;5:647-652.
12. Lisanti MP, Scherer P, Tang ZL, et al. Caveolae, caveolin and caveolin-rich membrance domains. Trends Cell Biol. 1994;4:231-235.
13. Lisanti MP, Scherer PE, Tang ZL, et al. Caveolae and human disease: functional roles in transcytosis, potocytosis, signalling, and cell polarity. Semin Dev Biol. 1995;6:47-58.
14. North AJ, Galazkiewicz B, Byers TJ, et al. Complementary distributions of vinculin and dystrophin define two distinct sarcolemma domains in smooth muscle. J Cell Biol. 1993;129:1159-1167.
15. Tang ZL, Scherer PE, Okamoto T, et al. Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem. 1996;271:2255-2261.
16. Way M, Parton RG. M-caveolin, a muscle specific caveolin-related protein. FEBS Lett. 1995;376:108-112.
17. Weiss S, Goldblum J. Rhabdomyosarcoma. In: Enzinger and Weiss's Soft Tissue Tumors, 4th ed. St. Louis, MO: Mosby, Inc, 2001:785-835.
18. Schmidt RA, Cone R, Haas JE, et al. Diagnosis of rhabdomyosarcomas with HHF35, a monoclonal antibody directed against muscle actins. Am J Pathol. 1988;131:19-28.
19. Parham DM, Webber B, Holt H, et al. Immunohistochemical study of childhood rhabdomyosarcomas and related neoplasms: results of an Intergroup Rhabdomyosarcoma Study project. Cancer. 1991;67:3072-3080.
20. Skalli O, Gabbiani G, Babai F, et al. Intermediate filament proteins and actin isoforms as markers for soft tissue tumor differentiation and origin. II. Rhabdomyosarcomas. Am J Pathol. 1988;130:515-531.
21. Cerilli LA, Wick MR. Immunohistology of soft tissue and osseous neoplasms. In: Dabbs. Diagnostic Immunohistochemistiy. New York: Churchill Livingstone, 2002:59-112.
22. Hurlimann J. Desmin and neural marker expression in mesothelial cells and mesotheliomas. Hum Pathol. 1994;25:753-757.
23. Parham DM, Dias P, Kelly DR, et al. Desmin positivity in primitive neuroectodermal tumors of childhood. Am J Surg Pathol. 1992;16:483-492.
24. Dias P, Parham DM, Shapiro DN, et al. Myogenic regulatory protein (myoD1) expression in childhood solid tumors. Am J Pathol. 1990;137:1283-1291.
25. Davis RL, Cheng PF, Lassar AB, et al. The MyoD DNA binding domain contains a recognition code for muscle-specific gene activation. Cell. 1990;60:733-746.
26. Murre C, McCaw PS, Baltimore D. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell. 1989;56:777-783.
27. Weintraub H, Davis R, Tapscott S, et al. The myoD gene family: nodal point during specification of the muscle cell lineage. Science. 1991;251:761-766.
28. Wang NP, Marx J, McNutt MA, et al. Expression of myogenic regulatory proteins (myogenin and myoD1) in small blue round cell tumors of childhood. Am J Pathol. 1995;147:1799-1810.
29. Kumar S, Perlman E, Harris CA, et al. Myogenin is a specific marker for rhabdomyosarcoma: an immunohistochemical study in paraffin embedded tissues. Mod Pathol. 2000;13:988-993.
30. Eusubi V, Damiani S, Pasquinelli G, et al. Small cell neuroendocrine carcinoma with skeletal muscle differentiation: report of three cases. Am J Surg Pathol. 2000;24:223-230.
31. Cessna MH, Zhou H, Perkins SL, et al. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? Am J Surg Pathol. 2001;25:1150-1157.
32. Biederer CH, Ries SJ, Moser M, et al. The basic helix-loop-helix transcription factors myogenin and Id2 mediate specific induction of caveolin-3 gene expression during embryonic development. J Biol Chem. 2000;275:26245-26251.
33. Dias P, Chen B, Dilday B, et al. Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. Am J Pathol. 2000;156:399-408.
34. Furlong MA, Mentzel T, Fanburg-Smith JC. Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers. Mod Pathol. 2001;14:595-603.
35. Lollini PL, De Giovanni C, Del Re B, et al. Myogenic differentiation of human rhabdomyosarcoma cells induced in vitro by antineoplastic drugs. Cancer Res. 1989;49:3631-3636.
36. Coffin CM, Rulon J, Smith L, et al. Pathologic features of rhabdomyosarcoma before and after treatment: a clinicopathologic and immunohistochemical analysis. Mod Pathol. 1997;10:1175-1187.
37. d'Amore ESG, Tollot M, Stracca-Pansa V, et al. Therapy associated differentiation in rhabdomyosarcomas. Mod Pathol. 1994;7:69-75.